MannKind Corporation (MNKD) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.07 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.06. Analysts expectations of $.03 million. During the same quarter in the previous year, the company posted $-0.07 EPS.
MannKind Corporation closed down -0.0157 points or -1.58% at $0.98 with 22,36,453 shares getting traded on Friday. Post opening the session at $0.9906, the shares hit an intraday low of $0.9742 and an intraday high of $1.01 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 18, 2016, Rosabel Realica Alinaya (SVP, Prin Acctg Officer) sold 6,294 shares at $1.06 per share price. According to the SEC, on May 18, 2016, Michael Castagna (Chief Commercial Officer) purchased 50,000 shares at $0.93 per share price. On May 26, 2015, Juergen Martens (COO) purchased 20,000 shares at $4.57 per share price, according to the Form-4 filing with the securities and exchange commission.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s product candidate is AFREZZA inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP) which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury Connecticut facility.